AU2011280907B2 - Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma - Google Patents

Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma Download PDF

Info

Publication number
AU2011280907B2
AU2011280907B2 AU2011280907A AU2011280907A AU2011280907B2 AU 2011280907 B2 AU2011280907 B2 AU 2011280907B2 AU 2011280907 A AU2011280907 A AU 2011280907A AU 2011280907 A AU2011280907 A AU 2011280907A AU 2011280907 B2 AU2011280907 B2 AU 2011280907B2
Authority
AU
Australia
Prior art keywords
precipitate
fraction
laip
composition
iaip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011280907A
Other languages
English (en)
Other versions
AU2011280907A1 (en
Inventor
Shawn F. Bairstow
Jennifer Hutsell
Sindhu Ramachandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2011280907A1 publication Critical patent/AU2011280907A1/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Application granted granted Critical
Publication of AU2011280907B2 publication Critical patent/AU2011280907B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011280907A 2010-07-23 2011-07-22 Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma Active AU2011280907B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23
US61/367,331 2010-07-23
PCT/US2011/045099 WO2012012773A1 (en) 2010-07-23 2011-07-22 Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma

Publications (2)

Publication Number Publication Date
AU2011280907A1 AU2011280907A1 (en) 2013-02-07
AU2011280907B2 true AU2011280907B2 (en) 2016-02-04

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011280907A Active AU2011280907B2 (en) 2010-07-23 2011-07-22 Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma

Country Status (14)

Country Link
US (2) US8841248B2 (https=)
EP (1) EP2596014B1 (https=)
JP (1) JP5830096B2 (https=)
KR (1) KR20130093607A (https=)
CN (1) CN103119058A (https=)
AU (1) AU2011280907B2 (https=)
BR (1) BR112013001753A2 (https=)
CA (1) CA2806645A1 (https=)
CO (1) CO6680653A2 (https=)
EA (1) EA201390156A1 (https=)
ES (1) ES2717177T3 (https=)
MX (1) MX2013000958A (https=)
SG (1) SG187599A1 (https=)
WO (1) WO2012012773A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN106928346B (zh) 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
US20210393750A1 (en) * 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
EP3994165A1 (en) * 2019-07-04 2022-05-11 CSL Behring GmbH Process for purifying c1-inh
EP4126930A1 (en) * 2020-03-31 2023-02-08 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
US20250281530A1 (en) * 2022-05-02 2025-09-11 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011260A1 (fr) * 1993-10-18 1995-04-27 Association Pour L'essor De La Transfusion Sanguine Dans La Region Du Nord Procede de preparation d'un concentre d'inter-alpha-trypsine inhibiteur a usage therapeutique et concentre obtenu
WO2005046587A2 (en) * 2003-11-08 2005-05-26 Prothera Biologics Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
ATE211486T1 (de) * 1995-09-22 2002-01-15 Zlb Bioplasma Ag Verfahren zur gewinnung von immunglobulinen aus fraktionen, die bei der fraktionierung von menschlichem blutplasma entstehen
EP1326893A2 (de) 2000-10-13 2003-07-16 Octapharma AG Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CN106928346B (zh) * 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011260A1 (fr) * 1993-10-18 1995-04-27 Association Pour L'essor De La Transfusion Sanguine Dans La Region Du Nord Procede de preparation d'un concentre d'inter-alpha-trypsine inhibiteur a usage therapeutique et concentre obtenu
WO2005046587A2 (en) * 2003-11-08 2005-05-26 Prothera Biologics Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
McCANN, K. B., et al., 'Evaluation of expanded bed adsorption chromatography for extraction of prothrombin complex from Cohn Supernatant I', Biologicals, 2008, vol. 36, pages 227-233 *

Also Published As

Publication number Publication date
EP2596014B1 (en) 2018-11-28
US8841248B2 (en) 2014-09-23
CO6680653A2 (es) 2013-05-31
CA2806645A1 (en) 2012-01-26
ES2717177T3 (es) 2019-06-19
KR20130093607A (ko) 2013-08-22
AU2011280907A1 (en) 2013-02-07
MX2013000958A (es) 2013-11-20
US20120053113A1 (en) 2012-03-01
EA201390156A1 (ru) 2014-01-30
JP2013535468A (ja) 2013-09-12
EP2596014A1 (en) 2013-05-29
JP5830096B2 (ja) 2015-12-09
US9505814B2 (en) 2016-11-29
SG187599A1 (en) 2013-03-28
CN103119058A (zh) 2013-05-22
US20150045538A1 (en) 2015-02-12
BR112013001753A2 (pt) 2016-05-31
WO2012012773A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
AU2011280907B2 (en) Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma
US20240117009A1 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
US11891431B2 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
US9109044B2 (en) Manufacture of factor H (FH) and FH-derivatives from plasma
US20140275496A1 (en) Isolation of factor h from fraction i paste
HK40079365A (en) Removal of serine proteases by treatment with finely divided silicon dioxide
HK1183449B (en) Removal of serine proteases by treatment with finely divided silicon dioxide

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER APPLICANT(S): BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED